BRIEF-Equillium Announces Positive Topline Data From Type B Portion Of Phase 1b EQUALISE Study Of Itolizumab In Lupus Nephritis

Reuters04-01

April 1 (Reuters) - Equillium Inc :

* EQUILLIUM ANNOUNCES POSITIVE TOPLINE DATA FROM THE TYPE B PORTION OF THE PHASE 1B EQUALISE STUDY OF ITOLIZUMAB IN LUPUS NEPHRITIS

* EQUILLIUM INC: MORE THAN 80% OF SUBJECTS ACHIEVED >50% REDUCTION IN URINE PROTEIN CREATININE RATIO (UPCR)

* EQUILLIUM INC: ITOLIZUMAB DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2424456637?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-01 22:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424456637","market":"us","top_or_hot":-1,"title":"BRIEF-Equillium Announces Positive Topline Data From Type B Portion Of Phase 1b EQUALISE Study Of Itolizumab In Lupus Nephritis","media":"Reuters","content":"<html><body><p>April 1 (Reuters) - Equillium Inc   :</p><p>   * EQUILLIUM ANNOUNCES POSITIVE TOPLINE DATA FROM THE TYPE B PORTION OF THE PHASE 1B EQUALISE STUDY OF ITOLIZUMAB IN LUPUS NEPHRITIS</p><p>   * <a href=\"https://laohu8.com/S/0A4D.UK\">EQUILLIUM INC</a>: MORE THAN 80% OF SUBJECTS ACHIEVED &gt;50% REDUCTION IN URINE PROTEIN CREATININE RATIO (UPCR)</p><p>   * EQUILLIUM INC: ITOLIZUMAB DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Equillium Announces Positive Topline Data From Type B Portion Of Phase 1b EQUALISE Study Of Itolizumab In Lupus Nephritis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Equillium Announces Positive Topline Data From Type B Portion Of Phase 1b EQUALISE Study Of Itolizumab In Lupus Nephritis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-01 22:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 1 (Reuters) - Equillium Inc   :   * EQUILLIUM ANNOUNCES POSITIVE TOPLINE DATA FROM THE TYPE B PORTION OF THE PHASE 1B EQUALISE STUDY OF ITOLIZUMAB IN LUPUS NEPHRITIS   * EQUILLIUM INC: MORE THAN...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EQ","symbol_name":"Equillium Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2424456637","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424456637","pubTimestamp":1711981684,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 1  - Equillium Inc   :   * EQUILLIUM ANNOUNCES POSITIVE TOPLINE DATA FROM THE TYPE B PORTION OF THE PHASE 1B EQUALISE STUDY OF ITOLIZUMAB IN LUPUS NEPHRITIS   * EQUILLIUM INC: MORE THAN 80% OF SUBJECTS ACHIEVED >50% REDUCTION IN URINE PROTEIN CREATININE RATIO    * EQUILLIUM INC: ITOLIZUMAB DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILESource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EQ":"Equillium Inc.","BK4139":"生物科技","BK4568":"美国抗疫概念"},"translate_title":"简报——Equillium宣布伊托珠单抗治疗狼疮性肾炎1b期均衡研究B型部分的阳性顶线数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQ":0.9},"content_text":"April 1 (Reuters) - Equillium Inc   :   * EQUILLIUM ANNOUNCES POSITIVE TOPLINE DATA FROM THE TYPE B PORTION OF THE PHASE 1B EQUALISE STUDY OF ITOLIZUMAB IN LUPUS NEPHRITIS   * EQUILLIUM INC: MORE THAN 80% OF SUBJECTS ACHIEVED >50% REDUCTION IN URINE PROTEIN CREATININE RATIO (UPCR)   * EQUILLIUM INC: ITOLIZUMAB DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424456637"}